Hospira Cancer Drugs Clinical Pipeline Insight

Reports
Published
Number of pages
33

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
$500
CD-ROM Mail Delivery
$800
Hard Copy Mail Delivery
$800
Electronic Access - Multi-User License
$1000

“Hospira - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Hospira. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “3” cancer drugs in clinical pipeline and majority of them are in preregistration phase. There are 8 cancer drugs by Hospira which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Hospira - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Hospira

  1.1 Business Overview

  1.2 Hospira Cancer Pipeline Overview

 

2. Hospira Cancer Drugs in Preregistration Phase

  2.1 Rituximab Biosimilar - Celltrion

  2.2 Zoledronic Acid - Hospira

 

3. Hospira Cancer Drugs in Registered Phase

  3.1 Trastuzumab Biosimilar - Celltrion

 

4. Marketed Cancer Drugs by Hospira

  4.1 Clofarabine (Clolar & Evoltra)

  4.2 Raltitrexed (Tomudex)

  4.3 Leuprorelin (Eligard)

  4.4 Omacetaxine Mepesuccinate (Synribo)

  4.5 Pentostatin (Coforin, Nipent & Nipentin)

  4.6 Gemcitabine (Hospira)

  4.7 Docetaxel (Hospira)

  4.8 Topotecan (Hospira)

 

5. No Development Reported in Cancer Drugs in Clinical Pipeline

  5.1 Bevacizumab Biosimilar - Celltrion

  5.2 Cetuximab Biosimilar - Celltrion

 

6. Discontinued in Cancer Drugs in Clinical Pipeline

  6.1 E 21R 

Figure 1-1: Hospira Cancer Pipeline by Phase (%)

Figure 1-2: Hospira Cancer Pipeline by Phase (Number)

Figure 1-3: Hospira Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Hospira Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)